L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids, L-Ornithine and L-Aspartate. It is a key pharmacological agent in hepatology, primarily used for its detoxifying properties in hyperammonemic states, especially in hepatic encephalopathy. It acts as an ammonia scavenger by enhancing the urea cycle and glutamine synthesis in the liver and skeletal muscle, thereby reducing elevated blood ammonia levels. In the Indian context, it is widely prescribed for both acute and chronic liver conditions, including cirrhosis and drug-induced liver injury.
Adult: Oral: 3-6 grams per day in divided doses (e.g., 1-2 sachets of 3g each, twice or thrice daily). For the 150mg strength, this would equate to 20-40 tablets per day, which is impractical; therefore, 150mg is typically used in fixed-dose combinations. When used as a single ingredient, standard doses are 3g, 5g, etc. Please refer to specific brand prescribing information.
Note: Oral granules/sachets: Dissolve the contents of one sachet in a glass of water or juice and drink immediately. Tablets: Swallow whole with a sufficient amount of water. Best taken with meals to improve tolerance. For hepatic encephalopathy, it is often co-administered with lactulose, but not simultaneously (space by 1-2 hours).
L-Ornithine L-Aspartate reduces elevated blood ammonia through two primary mechanisms: 1) Enhancement of the Urea Cycle: L-Ornithine acts as a substrate and activator for two key enzymes, ornithine transcarbamylase and carbamoyl phosphate synthetase I, in the mitochondria of periportal hepatocytes, promoting the conversion of ammonia to urea. 2) Promotion of Glutamine Synthesis: L-Aspartate, along with glutamate, serves as a substrate for glutamine synthetase, primarily in perivenous hepatocytes and skeletal muscle. This enzyme converts ammonia and glutamate to non-toxic glutamine, providing an alternative ammonia detoxification pathway, especially when the urea cycle is compromised.
Pregnancy: Category C: Animal reproduction studies have not been conducted. Use only if clearly needed and potential benefit justifies the potential risk to the fetus. Data in pregnant women is limited.
Driving: LOLA itself is not known to impair driving ability. However, if used for hepatic encephalopathy, the underlying condition (drowsiness, confusion) can impair skills. Patients should be cautioned until mental status is clear.
| Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride) | Increased risk of hyperkalemia due to additive effects. | Major |
| Potassium Supplements/Salt Substitutes | Increased risk of hyperkalemia. | Major |
| Corticosteroids (e.g., Fludrocortisone) | Increased risk of sodium and fluid retention. | Moderate |
| Lactulose | Additive/synergistic effect in lowering ammonia. No harmful interaction, but administer separately to avoid rapid GI transit. | Minor |
Same composition (L-Ornithine L-Aspartate (150mg)), different brands: